Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18097655rdf:typepubmed:Citationlld:pubmed
pubmed-article:18097655lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18097655lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:18097655lifeskim:mentionsumls-concept:C0171023lld:lifeskim
pubmed-article:18097655lifeskim:mentionsumls-concept:C0035397lld:lifeskim
pubmed-article:18097655lifeskim:mentionsumls-concept:C1707719lld:lifeskim
pubmed-article:18097655lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:18097655pubmed:issue4lld:pubmed
pubmed-article:18097655pubmed:dateCreated2008-2-15lld:pubmed
pubmed-article:18097655pubmed:abstractTextHigh blockade of dopamine D2 receptors in the ventral striatum including the nucleus accumbens may interfere with reward anticipation and cause secondary negative symptoms such as apathy or anhedonia. This may not be the case with newer neuroleptics such as olanzapine, which show less dopamine D2 receptor blockade and a faster off-rate from the receptor.lld:pubmed
pubmed-article:18097655pubmed:languageenglld:pubmed
pubmed-article:18097655pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:citationSubsetIMlld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18097655pubmed:statusMEDLINElld:pubmed
pubmed-article:18097655pubmed:monthMarlld:pubmed
pubmed-article:18097655pubmed:issn0033-3158lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:JuckelGeorgGlld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:GallinatJürge...lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:KnutsonBrianBlld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:SchlagenhaufF...lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:KoslowskiMich...lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:HeinzAndreasAlld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:WraseJanaJlld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:KienastThorst...lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:KahntThorsten...lld:pubmed
pubmed-article:18097655pubmed:authorpubmed-author:DemblerTheres...lld:pubmed
pubmed-article:18097655pubmed:issnTypePrintlld:pubmed
pubmed-article:18097655pubmed:volume196lld:pubmed
pubmed-article:18097655pubmed:ownerNLMlld:pubmed
pubmed-article:18097655pubmed:authorsCompleteYlld:pubmed
pubmed-article:18097655pubmed:pagination673-84lld:pubmed
pubmed-article:18097655pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:meshHeadingpubmed-meshheading:18097655...lld:pubmed
pubmed-article:18097655pubmed:year2008lld:pubmed
pubmed-article:18097655pubmed:articleTitleReward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.lld:pubmed
pubmed-article:18097655pubmed:affiliationDepartment of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany.lld:pubmed
pubmed-article:18097655pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18097655pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18097655pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18097655lld:pubmed